United Arab EmiratesTuberculosis profile
Population  2017 9.4 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.065 (0.038–0.1) 0.69 (0.4–1.1)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.01 (0.01–0.02)
Incidence  (includes HIV+TB) 0.076 (0.065–0.088) 0.81 (0.69–0.93)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.08 (0.06–0.09)
Incidence (MDR/RR-TB)** <0.01 (<0.01–<0.01) 0.04 (0.02–0.07)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females <0.01 (<0.01–<0.01) 0.029 (0.027–0.032) 0.033 (0.03–0.037)
Males <0.01 (<0.01–<0.01) 0.038 (0.034–0.042) 0.042 (0.038–0.047)
Total <0.01 (<0.01–<0.01) 0.067 (0.058–0.077) 0.076 (0.065–0.088)
TB case notifications, 2017  
Total cases notified 70
Total new and relapse 66
          - % tested with rapid diagnostics at time of diagnosis 44%
          - % with known HIV status 89%
          - % pulmonary 74%
          - % bacteriologically confirmed among pulmonary 96%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.88 (0.17–1)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 5 8%
          - on antiretroviral therapy 5 100%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  3
(1–5)
Estimated % of TB cases with MDR/RR-TB 3.7% (2–5.9) 25% (0.63–81)  
% notified tested for rifampicin resistance 54% 80% 39
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 1, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 0, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 88% 64
Previously treated cases, excluding relapse, registered in 2016 67% 3
HIV-positive TB cases registered in 2016 60% 5
MDR/RR-TB cases started on second-line treatment in 2015   0
XDR-TB cases started on second-line treatment in 2015   0
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment 11%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
37% (28–58)
TB financing, 2018  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-09-25 Data: www.who.int/tb/data